Evidence map›Paper›PMID 32992344›Full record

ArticleBlood2021

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

Andreas Agathangelidis, Anastasia Chatzidimitriou, Katerina Gemenetzi, Veronique Giudicelli, Maria Karypidou, Karla Plevova, Zadie Davis, Xiao-Jie Yan, Sabine Jeromin, Christof Schneider and 73 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 1 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. IMGTAntibodies (Basel, Switzerland) · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. IGLV3-21Haematologica · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

83 authors at 20 institutions in 20 countries.

Andreas AgathangelidisInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Anastasia ChatzidimitriouInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Katerina GemenetziInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Veronique GiudicelliInternational ImMunoGeneTics Information System (IMGT), Laboratoire d'ImmunoGénétique Moléculaire (LIGM), Institut de Génétique Humaine (IGH), Unité Mixte de Recherche (UMR), Centre National de la Recherche Scientifique (CNRS), Université de Montpellier, Montpellier, France.
Maria KarypidouInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Karla PlevovaDepartment of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University-University Hospital Brno, Brno, Czech Republic.
Zadie DavisDepartment of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom.
Xiao-Jie YanThe Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY.
Sabine JerominMLL Munich Leukemia Laboratory, Munich, Germany.
Christof SchneiderUniversity Hospital Medical Center, Ulm, Germany.
Lone Bredo PedersenDeparment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Renee C TschumperDepartment of Immunology, Mayo Clinic, Rochester, MN.
Lesley-Ann SuttonDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Panagiotis BaliakasScience for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Lydia ScarfòStrategic Research Program on CLL, B-Cell Neoplasia Unit, Division of Experimental Oncology, Università Vita-Salute San Raffaele/Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.
Ellen J van GastelLaboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center (UMC), Rotterdam, The Netherlands.
Marine ArmandAssistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne Université, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.
Eugen TauschDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Bella BidermanNational Research Center for Hematology, Moscow, Russia.
Constance BaerMLL Munich Leukemia Laboratory, Munich, Germany.
Davide BagnaraDepartment of Experimental Medicine, University of Genoa, Genoa, Italy.
Alba NavarroCentro de Investigacion Biomedica en Red en Oncologia (CIBERONC), Madrid, Spain.
Anne Langlois de SeptenvilleAssistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Department of Biological Hematology, Sorbonne Université, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.
Valentina GuidoMolecular Pathology Unit, Haematology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
Gerlinde Mitterbauer-HohendannerDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Aleksandar DimovskiFaculty of Pharmacy, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Northern Macedonia.
Christian BrieghelDeparment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Sarah LawlessClinical Haematology, Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, United Kingdom.
Manja MeggendorferMLL Munich Leukemia Laboratory, Munich, Germany.
Kamila BrazdilovaDepartment of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University-University Hospital Brno, Brno, Czech Republic.
Matthias RitgenSecond Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Monica FaccoHematology and Clinical Immunology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Cristina TresoldiDivision of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Andrea VisentinHematology and Clinical Immunology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Andrea PatriarcaDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont-Ospedale Maggiore della Carità, Novara, Italy.
Mark CatherwoodClinical Haematology, Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, United Kingdom.
Lisa BonelloGeneral Anatomopathology and Molecular Oncogenetics, Azienda Ospedaliero Universitaria (AOU), City of Health and Science of Turin, Turin, Italy.
Andrey SudarikovNational Research Center for Hematology, Moscow, Russia.
Katrina VanuraDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Maria RoumeliotiFirst Department of Propaedeutic Medicine, University of Athens, Athens, Greece.
Hana Skuhrova FrancovaDepartment of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University-University Hospital Brno, Brno, Czech Republic.
Theodoros MoysiadisInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Silvio VeroneseMolecular Pathology Unit, Haematology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
Krzysztof GiannopoulosExperimental Hematooncology Department, Medical University of Lublin, Lublin, Poland.
Larry MansouriDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Teodora Karan-DjurasevicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
Raphael SandaltzopoulosDepartment of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece.
Csaba BödörMTA-SE Momentum Molecular Oncohematology Research Group, First Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Franco FaisDepartment of Experimental Medicine, University of Genoa, Genoa, Italy.
Arnon P KaterDepartment of Hematology, Amsterdam Infection and Immunity Institute, Cancer Center Amsterdam, Amsterdam UMC-University of Amsterdam, Amsterdam, The Netherlands.
Irina PanovskaDepartment of Hematology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Northern Macedonia.
Davide RossiDivision of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Salem AlshemmariDepartment of Medicine, Faculty of Medicine, Kuwait University, Safat, Kuwait.
Panagiotis PanagiotidisFirst Department of Propaedeutic Medicine, University of Athens, Athens, Greece.
Paul CosteasThe Center for the Study of Haematological Malignancies, Nicosia, Cyprus.
Blanca EspinetLaboratorio de Citogenètica Molecular, Laboratori de Citologia Hematològica, Servei de Patologia i Servei de Hematologia, Hospital del Mar, Barcelona, Spain.
Darko AnticClinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia.
Letizia ForoniHammersmith Hospital, London, United Kingdom.
Marco MontilloMolecular Pathology Unit, Haematology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
Livio TrentinHematology and Clinical Immunology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Niki StavroyianniHematocrit (HCT) Unit, Hematology Department, G. Papanicolaou Hospital, Thessaloniki, Greece.
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont-Ospedale Maggiore della Carità, Novara, Italy.
Paola Francia di CelleGeneral Anatomopathology and Molecular Oncogenetics, Azienda Ospedaliero Universitaria (AOU), City of Health and Science of Turin, Turin, Italy.
Carsten NiemannDeparment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Elias CampoCentro de Investigacion Biomedica en Red en Oncologia (CIBERONC), Madrid, Spain.
Achilles AnagnostopoulosHammersmith Hospital, London, United Kingdom.
Christiane PottSecond Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Kirsten FischerUniversity Hospital Cologne, Cologne, Germany.
Michael HallekDepartment I of Internal Medicine, University of Cologne, Cologne, Germany.
David OscierDepartment of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom.
Stephan StilgenbauerDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Claudia HaferlachMLL Munich Leukemia Laboratory, Munich, Germany.
Diane JelinekDepartment of Immunology, Mayo Clinic, Scottsdale, AZ.
Nicholas ChiorazziThe Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY.
Sarka PospisilovaDepartment of Internal Medicine, Hematology and Oncology, Faculty of Medicine, Masaryk University-University Hospital Brno, Brno, Czech Republic.
Marie-Paule LefrancInternational ImMunoGeneTics Information System (IMGT), Laboratoire d'ImmunoGénétique Moléculaire (LIGM), Institut de Génétique Humaine (IGH), Unité Mixte de Recherche (UMR), Centre National de la Recherche Scientifique (CNRS), Université de Montpellier, Montpellier, France.
Sofia KossidaInternational ImMunoGeneTics Information System (IMGT), Laboratoire d'ImmunoGénétique Moléculaire (LIGM), Institut de Génétique Humaine (IGH), Unité Mixte de Recherche (UMR), Centre National de la Recherche Scientifique (CNRS), Université de Montpellier, Montpellier, France.
Anton W LangerakLaboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center (UMC), Rotterdam, The Netherlands.
Chrysoula BelessiHematology Department, Nikea General Hospital, Pireaus, Greece; and.
Frederic DaviLaboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center (UMC), Rotterdam, The Netherlands.
Richard RosenquistDepartment of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Paolo GhiaStrategic Research Program on CLL, B-Cell Neoplasia Unit, Division of Experimental Oncology, Università Vita-Salute San Raffaele/Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.
Kostas StamatopoulosInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Karolinska Institutet · SEMunich Leukemia Laboratory (Germany) · DEAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITCentral European Institute of Technology · CZCentre for Research and Technology Hellas · GRCentre National de la Recherche Scientifique · FRCopenhagen University Hospital · DKErasmus MC · NLUniversity of Padua · ITVita-Salute San Raffaele University · ITBelfast Health and Social Care Trust · GBDemocritus University of Thrace · GRHammersmith Hospital · GBMayo Clinic in Arizona · USMedical University of Vienna · ATNational and Kapodistrian University of Athens · GRNational Medical Research Center for Hematology · RUNorthwell Health · USOspedale Sant'Anna · ITRoyal Bournemouth Hospital · GB

Funding

Th17 generation, action and therapeutic relevance in chronic lymphocytic leukemiaR01CA238523 · NCI · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI CHIORAZZI, NICHOLAS, SHERRY, BARBARA A · 2020 to 2024
$2.7M
NCI NIH HHS R01 CA238523
6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent clinicobiological profiles, suggesting that the study of BcR immunoglobulin stereotypy in CLL has important implications for understanding disease pathophysiology and refining clinical decision-making. Nevertheless, several issues remain open, especially pertaining to the actual frequency of BcR immunoglobulin stereotypy and major subsets, as well as the existence of higher-order connections between individual subsets. To address these issues, we investigated clonotypic IGHV-IGHD-IGHJ gene rearrangements in a series of 29 856 patients with CLL, by far the largest series worldwide. We report that the stereotyped fraction of CLL peaks at 41% of the entire cohort and that all 19 previously identified major subsets retained their relative size and ranking, while 10 new ones emerged; overall, major stereotyped subsets had a cumulative frequency of 13.5%. Higher-level relationships were evident between subsets, particularly for major stereotyped subsets with unmutated IGHV genes (U-CLL), for which close relations with other subsets, termed "satellites," were identified. Satellite subsets accounted for 3% of the entire cohort. These results confirm our previous notion that major subsets can be robustly identified and are consistent in relative size, hence representing distinct disease variants amenable to compartmentalized research with the potential of overcoming the pronounced heterogeneity of CLL. Furthermore, the existence of satellite subsets reveals a novel aspect of repertoire restriction with implications for refined molecular classification of CLL.

Indexed as

Gene FrequencyGene RearrangementHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionLeukemia, Lymphocytic, Chronic, B-CellSomatic Hypermutation, ImmunoglobulinImmunoglobulin Heavy ChainsImmunoglobulin Variable Region

Identifiers

PMID32992344
PMCPMC7976441
OpenAlexW3090488793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.